Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592501 · ClinicalTrials.gov registry record · Phase 2
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00592501: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00592501 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00592501, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Photon beam radiation is the standard type of radiation used to treat nasopharyngeal carcinoma. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor and leaves the body through healthy tissue. Proton beam radiation has been shown to have the same effect on tumors as photon beam radiation but it enters the body, passes through healthy tissue, and encounters the tumor but then stops. This means less healthy tissue is affected by proton beam treatment than by photon beam treatment. The purpose of this study is to determine the effectiveness of proton beam radiation in treating nasopharyngeal cancer and reducing the acute and long-term side effects from the treatment. This study will also test to see if the sparing of the healthy tissue can improve quality of life
Interventions
- DRUG Cisplatin
- DRUG Fluorouracil
- RADIATION Proton/Photon Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-10 |
| Est. Completion | 2019-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592501
The ClinicalTrials.gov registry entry for NCT00592501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00592501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592501 about?
NCT00592501 is a clinical study titled "Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma". Photon beam radiation is the standard type of radiation used to treat nasopharyngeal carcinoma. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor and leaves the body through healthy tissue. Proton beam radiation has been shown to have the same effect on tu...
What is the current status of trial NCT00592501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-10. Estimated completion is 2019-04.
What interventions are being tested in trial NCT00592501?
The interventions under investigation include: Cisplatin (DRUG), Fluorouracil (DRUG), Proton/Photon Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00592501?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.